MCID: RHM027
MIFTS: 61

Rheumatic Disease

Categories: Cardiovascular diseases, Immune diseases

Aliases & Classifications for Rheumatic Disease

MalaCards integrated aliases for Rheumatic Disease:

Name: Rheumatic Disease 12 15
Rheumatic Diseases 55
Collagen Diseases 73
Rheumatism 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1575
ICD10 33 I06.9 I09.9

Summaries for Rheumatic Disease

Disease Ontology : 12 An autoimmune hypersensitivity disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to spondyloarthropathy 1 and palindromic rheumatism, and has symptoms including myalgia, joint symptom and musculoskeletal symptom. An important gene associated with Rheumatic Disease is TRIM21 (Tripartite Motif Containing 21), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs leucovorin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Rheumatism or rheumatic disorder is an umbrella term for conditions causing chronic, often intermittent... more...

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 440)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 32.7 CRP TNF TNFRSF11B
2 palindromic rheumatism 32.4 CRP HLA-DRB1 IL1B TNF
3 systemic scleroderma 32.0 CENPB CRP IFNG SSB TLR9 TRIM21
4 rheumatoid arthritis 31.9 CRP HLA-DRB1 HMGB1 IFNG IL10 IL1B
5 arthritis 31.2 HLA-DRB1 IFNG IL10 IL1B PTGS2 TNF
6 osteoporosis 30.7 CRP IFNG IL1B TNF TNFRSF11B
7 lupus erythematosus 30.7 APOH IL10 SSB TNF TRIM21
8 pneumonia 30.6 CRP IL10 IL1B TLR9 TNF
9 vasculitis 30.6 APOH CRP TNF VCAM1
10 psoriatic arthritis 30.5 CRP HLA-DRB1 IL1B TNF TNFRSF11B
11 viral infectious disease 30.4 IFNA1 IFNG IL10 IL1B TLR9 TNF
12 arteries, anomalies of 30.2 CRP IL1B TLR9 TNF VCAM1
13 lyme disease 30.2 CRP IL1B TNF
14 arthropathy 30.2 CRP TNF TNFRSF11B
15 myasthenia gravis 30.2 IFNG IL10 TNF
16 lung disease 30.1 IL10 IL1B TLR9 TNF
17 interstitial lung disease 30.1 IFNG IL10 IL1B TNF
18 sjogren syndrome 30.1 APOH SSB TRIM21
19 human immunodeficiency virus infectious disease 30.1 IFNA1 IFNG IL10 TLR9 TNF
20 uveitis 30.1 IFNG IL10 IL1R1 IL2RA TNF
21 peptic ulcer disease 30.1 IL10 IL1B PTGS2 TNF
22 reactive arthritis 30.1 CRP IFNG IL10 TNF
23 cystitis 30.0 CRP PTGS2 TNF
24 synovitis 30.0 CRP IL1B TNF TNFRSF11B VCAM1
25 sleep apnea 30.0 CRP IL1B TNF
26 mixed connective tissue disease 30.0 APOH HLA-DRB1 IFNG IL10 RNPC3 TNF
27 connective tissue disease 30.0 APOH CENPB HLA-DRB1 IFNG IL10 RNPC3
28 hematopoietic stem cell transplantation 30.0 IFNG IL10 TNF
29 rheumatic fever 30.0 HLA-DRB1 IL10 TNF
30 demyelinating disease 30.0 IFNA1 IFNG IL10 IL1B TNF
31 bronchiolitis obliterans 30.0 IFNG IL10 TNF
32 rubella 30.0 HLA-DRB1 IL10 TNF
33 chronic fatigue syndrome 30.0 IL10 IL1B TNF
34 hepatitis a 30.0 IFNG IL10 TNF
35 juvenile rheumatoid arthritis 30.0 CRP HLA-DRB1 IL1B IL1R1 IL2RA TNF
36 psoriasis 29.9 IFNG IL10 IL1B TLR9 TNF
37 tetanus 29.9 IFNG IL10 IL2RA
38 diabetes mellitus 29.9 CRP HLA-DRB1 IFNG IL1B IL2RA TNF
39 pericarditis 29.9 CRP IFNG IL1B TNF
40 mumps 29.8 HLA-DRB1 IFNG IL2RA TNF
41 leprosy 3 29.8 HLA-DRB1 IFNG IL10 TNF
42 collagen disease 29.8 CENPB CRP SSB TLR9 TRIM21
43 placenta disease 29.8 APOH IL1B TLR9
44 chlamydia 29.8 CRP IFNG IL10 IL1B TNF
45 joint disorders 29.8 IL1B IL1R1 TNF
46 temporal arteritis 29.7 APOH CRP HLA-DRB1 IFNG TNF
47 endocarditis 29.7 APOH CRP IL10 TNF VCAM1
48 bronchiolitis 29.7 CRP IFNG IL10 TLR9 TNF
49 pulmonary tuberculosis 29.7 HLA-DRB1 IFNG IL10 TLR9 TNF
50 inflammatory bowel disease 29.7 CRP HLA-DRB1 IFNG IL10 IL1B IL1R1

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


myalgia, joint symptom, musculoskeletal symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.03 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 10.03 HMGB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.03 IL2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 10.03 APOH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.03 HMGB1 SSB
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.03 IL10 SSB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.03 APOH HMGB1 IL10 IL2RA SSB
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.03 HMGB1 IL2RA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.03 IL2RA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.03 SSB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.03 IL10 IL2RA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.03 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.03 APOH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.03 IL10 SSB
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.03 IL10
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 APOH IL10 IL1B IL2RA SSB TNF
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 APOH IL10 IL1B IL2RA SSB TNF

MGI Mouse Phenotypes related to Rheumatic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 IFNG IL10 IL1B IL1R1 IL2RA PTGS2
2 homeostasis/metabolism MP:0005376 9.93 APOH CRP IFNG IL10 IL1B IL1R1
3 immune system MP:0005387 9.77 CRP IFNG IL10 IL1B IL1R1 IL2RA
4 mortality/aging MP:0010768 9.47 APOH CENPB IFNG IL10 IL1B IL1R1

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 998)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
2
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
3
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 599-79-1 5353980 5359476
4
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118-42-3 3652
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
8
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
9
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
11
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
12
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
13
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
14
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9004-61-9 53477741
15
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
16
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2
17
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
18
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
19
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
20
Dalteparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6
21
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
22
Glucosamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3416-24-8 439213
23
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1177-87-3
26
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
27
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 378-44-9 9782
28
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
29
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
30
Rivaroxaban Approved Phase 4,Phase 3,Not Applicable 366789-02-8
31
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 1302 156391
32
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
33
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
34
Chitosan Approved Phase 4,Not Applicable 9012-76-4 71853
35
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
36
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 175805 71273
37
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51481-61-9 2756
38
Hyoscyamine Approved Phase 4,Not Applicable 101-31-5 64692
39
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
40
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
41 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
43
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 202409-33-4 123619
44
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
45
Fluorouracil Approved Phase 4 51-21-8 3385
46
Tacrolimus Approved, Investigational Phase 4,Phase 3,Early Phase 1 104987-11-3 445643 439492
47
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 332348-12-6 10237
48
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15307-86-5 3033
49
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
50
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160

Interventional clinical trials:

(show top 50) (show all 6698)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
3 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
5 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
6 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
7 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
8 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
9 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
10 Additional Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02949466 Phase 4 Triamcinolone
11 Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty Unknown status NCT02865174 Phase 4 Topical tranexamic acid;Floseal®;Enoxaparin
12 Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
13 Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
14 Primary Care Study With Chondroitin Sulfate and Glucosamine Hydrochloride in Hand Osteoarhritis Unknown status NCT02823548 Phase 4 Droglican;Placebo
15 Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN Unknown status NCT02821468 Phase 4 Droglican;Paracetamol or oral NSAIDs excluding COX2 inhibitors
16 Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial Unknown status NCT02760459 Phase 4 Dexamethasone;Normal saline solution
17 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
18 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
19 26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle Unknown status NCT02627859 Phase 4
20 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
21 Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections Unknown status NCT02612272 Phase 4 Ketorolac;Betamethasone
22 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
23 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
24 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
25 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
26 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
27 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
28 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
29 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
30 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
31 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
32 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
33 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
34 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
35 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
36 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
37 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
38 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
39 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
40 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
41 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
42 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
43 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
44 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
45 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
46 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
47 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
48 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
49 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
50 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

41
Bone, Testes, Heart, T Cells, Lung, Thyroid, Endothelial

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 1952)
# Title Authors Year
1
Children and young people get rheumatic disease too. ( 30473439 )
2019
2
Approach to Patients with Suspected Rheumatic Disease. ( 29759118 )
2018
3
Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. ( 29540190 )
2018
4
Confidence amongst Multidisciplinary Professionals in Managing Paediatric Rheumatic Disease in Australia. ( 29593902 )
2018
5
Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities. ( 29593551 )
2018
6
Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists. ( 29481725 )
2018
7
Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? ( 29437584 )
2018
8
Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. ( 29363290 )
2018
9
Rapid glucocorticoid tapering therapy to reduce mortality from pneumocystis pneumonia in patients with rheumatic disease. ( 29972334 )
2018
10
The Brave New World of Rheumatic Disease Research Today. ( 29622303 )
2018
11
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). ( 29574143 )
2018
12
Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor I+ Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry. ( 29517554 )
2018
13
Asymptomatic Rhabdomyolysis and Digital Necrosis-Clues for a Rheumatic Disease. ( 29742540 )
2018
14
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada. ( 29437583 )
2018
15
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology. ( 29875735 )
2018
16
Endothelial progenitor cells and rheumatic disease modifying therapy. ( 29842927 )
2018
17
Rheumatic Disease Autoantibodies in Patients with Autoimmune Thyroid Diseases. ( 29864750 )
2018
18
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. ( 29318514 )
2018
19
Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. ( 29391382 )
2018
20
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
2018
21
Rice-body formation without rheumatic disease or tuberculosis in a &amp;quot;sausage&amp;quot; ring finger. ( 29786532 )
2018
22
Translating GWAS in rheumatic disease: approaches to establishing mechanism and function for genetic associations with ankylosing spondylitis. ( 29741584 )
2018
23
Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. ( 29290190 )
2018
24
Brief Report: Exercise and Anxiety in Adults with Arthritis and Other Rheumatic Diseases: Support for Evidential Value. ( 30420959 )
2018
25
Seroprevalence of Anti-Citrullinated Protein Antibodies (ACPA) in Patients with Rheumatic Diseases other than Rheumatoid Arthritis. ( 30347947 )
2018
26
Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. ( 30206082 )
2018
27
Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. ( 30137592 )
2018
28
Functional MRI in rheumatic diseases with a focus on fibromyalgia. ( 30296992 )
2018
29
Clinical significance of fibromyalgia syndrome in different rheumatic diseases: Relation to disease activity and quality of life. ( 28411133 )
2018
30
Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs. ( 30187273 )
2018
31
Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. ( 30382902 )
2018
32
Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review. ( 30377772 )
2018
33
Safety of Etanercept in the treatment of rheumatic disease patients with Hepatitis C virus infection. ( 30091962 )
2018
34
Effects of patient satisfaction and confidence on the success of treatment of combined rheumatic disease and interstitial lung disease in a multidisciplinary outpatient clinic. ( 30146740 )
2018
35
Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. ( 29202589 )
2018
36
Thymectomy in patients with myasthenia gravis increases the risk of autoimmune rheumatic diseases: a nationwide cohort study. ( 30189048 )
2018
37
Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. ( 30337056 )
2018
38
Clinical characteristics of multifocal osteonecrosis in Korean patients with rheumatic disease. ( 28328178 )
2018
39
Osteoporosis in Rheumatic Diseases: Anti-rheumatic Drugs and the Skeleton. ( 29470611 )
2018
40
Clinical utilities of quantitative ultrasound in osteoporosis associated with inflammatory rheumatic diseases. ( 29541626 )
2018
41
Risk of autoimmune rheumatic diseases in patients with palindromic rheumatism: A nationwide, population-based, cohort study. ( 30048527 )
2018
42
Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. ( 30060102 )
2018
43
Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. ( 30449650 )
2018
44
Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. ( 30487148 )
2018
45
Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. ( 29508305 )
2018
46
Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study. ( 29920316 )
2018
47
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings. ( 30079593 )
2018
48
Prescribing for Children With Rheumatic Disease: Perceived Treatment Approaches Between Pediatric and Adult Rheumatologists. ( 28464558 )
2018
49
The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages. ( 29663334 )
2018
50
Sarcopenia: A Rheumatic Disease? ( 30001782 )
2018

Variations for Rheumatic Disease

Expression for Rheumatic Disease

Search GEO for disease gene expression data for Rheumatic Disease.

Pathways for Rheumatic Disease

Pathways related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CRP HLA-DRB1 HMGB1 IFNA1 IFNG IL10
2
Show member pathways
13.72 IFNA1 IFNG IL10 IL1B IL1R1 IL2RA
3
Show member pathways
13.27 HLA-DRB1 HMGB1 IFNG IL1B IL1R1 IL2RA
4
Show member pathways
13.14 HLA-DRB1 IFNA1 IFNG IL10 IL1B IL1R1
5
Show member pathways
13.05 IFNA1 IFNG IL10 IL1B TLR9 TNF
6
Show member pathways
12.94 HLA-DRB1 IFNA1 IFNG IL10 IL1B IL2RA
7
Show member pathways
12.86 HLA-DRB1 IFNA1 IFNG IL1B IL2RA TLR9
8
Show member pathways
12.8 HMGB1 IFNA1 IFNG IL1B TNF
9
Show member pathways
12.68 HLA-DRB1 IFNG IL10 IL2RA TNF
10
Show member pathways
12.66 IL1B IL1R1 TLR9 TNF TNFRSF11B
11
Show member pathways
12.62 HLA-DRB1 IFNG IL10 IL1B IL1R1 IL2RA
12
Show member pathways
12.6 HLA-DRB1 IFNA1 IFNG TRIM21 VCAM1
13 12.49 HLA-DRB1 IL1R1 IL2RA TNF VCAM1
14
Show member pathways
12.44 IL10 PTGS2 TNFRSF11B VCAM1
15
Show member pathways
12.44 IFNG IL10 IL1B TNF
16
Show member pathways
12.4 CRP IFNG IL1B PTGS2 TNF
17
Show member pathways
12.38 IFNG IL1B